Skip to content
Search

Latest Stories

Pharmacy contraception service sees steady growth, but funding and access issues persist

Pharmacy contraception service sees steady growth, but funding and access issues persist

The pharmacy contraception service was expanded to enable all pharmacists to initiate oral contraception last year 

Since the launch of the tier 2 NHS pharmacy contraception service in December 2023, over 8,500 initiation consultations have been conducted in England, according to data from the NHS Business Services Authority (NHS BSA).


The NHS BSA data obtained by The Pharmaceutical Journal showed that between December 2023 and April 2024, community pharmacies completed 8,531 contraception service initiation consultations.

Tier 2 of the service enables community pharmacists to begin oral contraceptive treatment through a patient group direction.

It builds on tier 1 service, which focuses on the ongoing monitoring and supply of repeat oral contraception prescriptions.

As per the latest data, community pharmacies carried out 48,234 consultations under tier 1 of the service between December 2023 and April 2024.

Furthermore, the NHS BSA data indicated a steady rise in the number of initiation consultations each month.

In February 2024, pharmacies carried out 1,837 consultations, increasing to 2,235 in March 2024 and reaching 2,803 consultations in April 2024.

The Department of Health and Social Care (DHSC) announced in January 2024 that almost 3,000 contractors had signed up for the expanded NHS England Pharmacy Contraception Service.

This figure was included in a statement released on 17 January 2024, announcing the government's women's health priorities for the year.

However, the NHS BSA data showed that 1,240 contractors conducted 2,803 initiation consultations in April 2024.

Jasmine Shah, head of advice and support at the National Pharmacy Association, stated that the growing number of pharmacy consultations for initiating oral contraception highlights the importance of “choice for women.”

“Pharmacies are convenient and non-stigmatising places to access sexual and reproductive health services,” she told The Pharmaceutical Journal.

However, she pointed out that the service was introduced against the backdrop of years of underfunding, which has reduced the resources needed to implement new NHS services and slowed engagement.

Meanwhile, Tase Oputu, chair of the Royal Pharmaceutical Society’s English Pharmacy Board, emphasised the urgent need to address the “gap in emergency contraception services.”

“Women across England should have equal, free access to emergency contraception through community pharmacies like women in Scotland and Wales,” she said.

Oputu called on the NHS to standardise this service to promote fairness and ease the burden on other healthcare services.

The pharmacy contraception service was expanded to enable all pharmacists to initiate oral contraception starting 1 December 2023, as part of NHS England's ‘Delivery Plan for Recovering Access to Primary Care’.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less